Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 4, 2013, Pages 435-440

  Daver, Naval ^a   Liu Dumlao, Theresa ^a   Ravandi, Farhad ^a   Pierce, Sherry ^a   Borthakur, Gautam ^a   Pemmaraju, Naveen ^a   Nazha, Aziz ^a   Faderl, Stefan ^a   Jabbour, Elias ^a   Garcia Manero, Guillermo ^a   Cortes, Jorges ^a   Kantarjian, Hagop ^a   Quintás Cardama, Alfonso ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myeloid leukemia; Cytotoxic chemotherapy; Elderly; FLT3; NPM1

Indexed keywords

CD135 ANTIGEN; CYTARABINE; IDARUBICIN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HETEROZYGOTE; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; WILD TYPE;

ACUTE MYELOID LEUKEMIA; CYTOTOXIC CHEMOTHERAPY; ELDERLY; FLT3; NPM1;

AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84880720652     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.02.021     Document Type: Article

References (38)

1. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD [Web site]. Available at: http://seer.cancer.gov/csr/1975-2010/. Accessed: April 2013.
2. E. Estey Acute myeloid leukemia and myelodysplastic syndromes in older patients J Clin Oncol 25 2007 1908 1915 (Pubitemid 46854425)
3. E.H. Estey Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management Am J Hematol 87 2012 89 99
4. E.H. Estey Older adults: should the paradigm shift from standard therapy? Best Pract Res Clin Haematol 21 2008 61 66 (Pubitemid 351377510)
5. D. Grimwade, H. Walker, and G. Harrison The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial Blood 98 2001 1312 1320
6. S. Frohling, R.F. Schlenk, and S. Kayser Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B Blood 108 2006 3280 3288
7. S.S. Farag, K.J. Archer, and K. Mrozek Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461 Blood 108 2006 63 73 (Pubitemid 43996625)
8. H. Dohner, E.H. Estey, and S. Amadori Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood 115 2010 453 474
9. H. Kantarjian, F. Ravandi, and S. O'Brien Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia Blood 116 2010 4422 4429
10. G. Marcucci, T. Haferlach, and H. Dohner Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications J Clin Oncol 29 2011 475 486
11. R.F. Schlenk, K. Dohner, and J. Krauter Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 2008 1909 1918 (Pubitemid 351620111)
12. P.D. Kottaridis, R.E. Gale, and M.E. Frew The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 98 2001 1752 1759
13. C. Thiede, C. Steudel, and B. Mohr Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 99 2002 4326 4335 (Pubitemid 34627197)
14. S. Schnittger, C. Schoch, and W. Kern FLT3 length mutations in AML: correlation to cytogenetics, FAB-subtype, and prognosis in 652 patients Blood 96 2000 (abstract 826a)
15. J.P. Patel, M. Gonen, and M.E. Figueroa Prognostic relevance of integrated genetic profiling in acute myeloid leukemia N Engl J Med 366 2012 1079 1089
16. H. Kiyoi, T. Naoe, and Y. Nakano Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia Blood 93 1999 3074 3080 (Pubitemid 29200800)
17. P. Lin, D. Jones, and L.J. Medeiros Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia Am J Clin Pathol 126 2006 530 533 (Pubitemid 44498502)
18. D. Jones, H. Yao, and A. Romans Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias Genes Chromosomes Cancer 49 2010 182 191
19. S. Konoplev, X. Huang, and H.A. Drabkin Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis Cancer 115 2009 4737 4744
20. L.G. Shaffer, and N. Tommerup ISCN 2005: An International System for Human Cytogenetic Nomenclature 2005 S Karger Basel, Switzerland
21. J.W. Vardiman, J. Thiele, and D.A. Arber The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 2009 937 951
22. B.D. Cheson, J.M. Bennett, and K.J. Kopecky Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia J Clin Oncol 21 2003 4642 4649 (Pubitemid 46594039)
23. E.H. Estey, H. Kantarjian, and M. Keating Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome Semin Oncol 20 1993 1 5 (Pubitemid 24013202)
24. S. Faderl, S. Verstovsek, and J. Cortes Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older Blood 108 2006 45 51 (Pubitemid 43990611)
25. E. Jabbour, H. Kantarjian, and F. Ravandi A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome Cancer 117 2011 1236 1244
26. E.H. Estey, P.F. Thall, and S. Pierce Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome Blood 93 1999 2478 2484 (Pubitemid 29181178)
27. D. Grimwade, H. Walker, and F. Oliver The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties Blood 92 1998 2322 2333 (Pubitemid 28452973)
28. A.H. Goldstone, A.K. Burnett, and I. Avivi Secondary acute myeloid leukaemia has a worse outcome than de novo AML, even taking into account cytogenetics and age. AML 10,11,12 MRC trials Blood 100 2002 (abstract 88a)
29. H. Kantarjian, S. O'Brien, and J. Cortes Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome Cancer 106 2006 1090 1098
30. C. Schoch, W. Kern, and S. Schnittger The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups Haematologica 89 2004 1082 1090 (Pubitemid 39295479)
31. T. Buchner, W.E. Berdel, and B. Wormann Treatment of older patients with AML Crit Rev Oncol Hematol 56 2005 247 259 (Pubitemid 41568580)
32. F.R. Appelbaum, H. Gundacker, and D.R. Head Age and acute myeloid leukemia Blood 107 2006 3481 3485
33. E. Estey, T.L. Smith, and M.J. Keating Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia Leukemia 3 1989 257 263 (Pubitemid 19092757)
34. E.H. Estey, P.F. Thall, and J.E. Cortes Comparison of idarubicin + ara-C-, fludarabine + ara-C, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts Blood 98 2001 3575 3583
35. A.V. Moorman, E. Roman, and E.V. Willett Karyotype and age in acute myeloid leukemia. Are they linked? Cancer Genet Cytogenet 126 2001 155 161 (Pubitemid 32453333)
36. R.F. Schlenk, and K. Dohner Impact of new prognostic markers in treatment decisions in acute myeloid leukemia Curr Opin Hematol 16 2009 98 104
37. S. Schnittger, C. Schoch, and M. Dugas Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease Blood 100 2002 59 66 (Pubitemid 35177429)
38. D.L. Stirewalt, K.J. Kopecky, and S. Meshinchi FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia Blood 97 2001 3589 3595